Canada markets open in 8 hours 10 minutes

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.90-0.13 (-0.54%)
At close: 04:00PM EDT
23.90 0.00 (0.00%)
After hours: 05:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close24.03
Open24.06
Bid0.00 x 0
Ask0.00 x 0
Day's Range23.41 - 24.26
52 Week Range13.82 - 25.95
Volume785,278
Avg. Volume722,195
Market Cap2.163B
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

    New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancerSALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad’s MyChoice

  • GlobeNewswire

    Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

    SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen. The panel includes 39 conditions and screens up to 272 genes associated with serious inherited conditions. The conditions added to the Universal Plus panel were named in the American College of Medical Genetics and Genomics (ACMG) practice resource for carrier screen

  • GlobeNewswire

    Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

    SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyre